Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy

被引:248
作者
Kaufmann, GR
Furrer, H
Ledergerber, B
Perrin, L
Opravil, M
Vernazza, P
Cavassini, M
Bernasconi, E
Rickenbach, M
Hirschel, B
Battegay, M
机构
[1] Univ Basel Hosp, Dept Internal Med, Div Infect Dis & Hosp Epidemiol, CH-4031 Basel, Switzerland
[2] Univ Basel Hosp, Med Outpatient Dept, CH-4031 Basel, Switzerland
[3] Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland
[4] Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland
[5] Cantonal Hosp St Gallen, Dept Internal Med, St Gallen, Switzerland
[6] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland
[7] Univ Hosp Geneva, Virol Lab, Geneva, Switzerland
[8] CHU Vaudois, Div Infect Dis, Lausanne, Switzerland
[9] CHU Vaudois, Ctr Data, Swiss HIV Cohort Study, Lausanne, Switzerland
[10] Reg Hosp Lugano, Dept Internal Med, Lugano, Switzerland
关键词
D O I
10.1086/431484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The CD4 T cell count recovery in human immunodeficiency virus type 1 ( HIV- 1) - infected individuals receiving potent antiretroviral therapy ( ART) shows high variability. We studied the determinants and the clinical relevance of incomplete CD4 T cell restoration. Methods. Longitudinal CD4 T cell count was analyzed in 293 participants of the Swiss HIV Cohort Study who had had a plasma HIV- 1 RNA load < 1000 copies/ mL for >= 5 years. CD4 T cell recovery was stratified by CD4 T cell count 5 years after initiation of ART ( >= 500 cells/ mL was defined as a complete response, and < 500 cells/ mL was defined as an incomplete response). Determinants of incomplete responses and clinical events were evaluated using logistic regression and survival analyses. Results. The median CD4 T cell count increased from 180 cells/ mL at baseline to 576 cells/ mL 5 years after ART initiation. A total of 35.8% of patients were incomplete responders, of whom 47.6% reached a CD4 T cell plateau < 500 cells/ mu L. Centers for Disease Control and Prevention HIV- 1 disease category B and/ or C events occurred in 21% of incomplete responders and in 14.4% of complete responders (). Older age ( adjusted P > 1.05 odds ratio [ aOR], 1.71 per 10- year increase; 95% confidence interval [ CI], 1.21 - 2.43), lower baseline CD4 T cell count ( aOR, 0.37 per 100- cell increase; 95% CI, 0.28 - 0.49), and longer duration of HIV infection ( aOR, 2.39 per 10- year increase; 95% CI, 1.19 - 4.81) were significantly associated with a CD4 T cell count ! 500 cells/ mL at 5 years. The median increases in CD4 T cell count after 3 - 6 months of ART were smaller in incomplete responders () and predicted, in conjunction with baseline CD4 T cell count and age, incomplete response with 80% P < 001 sensitivity and 72% specificity. Conclusion. Individuals with incomplete CD4 T cell recovery to < 500 cells/ mu L had more advanced HIV- 1 infection at baseline. CD4 T cell changes during the first 3 - 6 months of ART already reflect the capacity of the immune system to replenish depleted CD4 T lymphocytes.
引用
收藏
页码:361 / 372
页数:12
相关论文
共 29 条
[11]   Immune reconstitution in HIV-infected patients [J].
Hirsch, HH ;
Kaufmann, G ;
Sendi, P ;
Battegay, M .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (08) :1159-1166
[12]   Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy [J].
Hunt, PW ;
Deeks, SG ;
Rodriguez, B ;
Valdez, H ;
Shade, SB ;
Abrams, DI ;
Kitahata, MM ;
Krone, M ;
Neilands, TB ;
Brand, RJ ;
Lederman, MM ;
Martin, JN .
AIDS, 2003, 17 (13) :1907-1915
[13]   T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy [J].
Hunt, PW ;
Martin, JN ;
Sinclair, E ;
Bredt, B ;
Hagos, E ;
Lampiris, H ;
Deeks, SG .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (10) :1534-1543
[14]   CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years - The Swiss HIV cohort study [J].
Kaufmann, GR ;
Perrin, L ;
Pantaleo, G ;
Opravil, M ;
Furrer, H ;
Telenti, A ;
Hirschel, B ;
Ledergerber, B ;
Vernazza, P ;
Bernasconi, E ;
Rickenbach, M ;
Egger, M ;
Battegay, M .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (18) :2187-2195
[15]   Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy [J].
Kaufmann, GR ;
Bloch, M ;
Zaunders, JJ ;
Smith, D ;
Cooper, DA .
AIDS, 2000, 14 (08) :959-969
[16]   Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection [J].
Kaufmann, GR ;
Zaunders, JJ ;
Cunningham, P ;
Kelleher, AD ;
Grey, P ;
Smith, D ;
Carr, A ;
Cooper, DA .
AIDS, 2000, 14 (17) :2643-2651
[17]   The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy [J].
Kaufmann, GR ;
Bloch, M ;
Finlayson, R ;
Zaunders, J ;
Smith, D ;
Cooper, DA .
AIDS, 2002, 16 (03) :359-367
[18]   Relative significance of different pathways of immune reconstitution in HIV type 1 infection as estimated by mathematical modeling [J].
Kaufmann, GR ;
Zaunders, J ;
Murray, J ;
Kelleher, AD ;
Lewin, SR ;
Solomon, A ;
Smith, D ;
Cooper, DA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (02) :147-159
[19]   Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir [J].
Kelleher, AD ;
Carr, A ;
Zaunders, J ;
Cooper, DA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :321-329
[20]   Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study [J].
Ledergerber, B ;
Egger, M ;
Opravil, M ;
Telenti, A ;
Hirschel, B ;
Battegay, M ;
Vernazza, P ;
Sudre, P ;
Flepp, M ;
Furrer, H ;
Francioli, P ;
Weber, R .
LANCET, 1999, 353 (9156) :863-868